2010•Modern Diagnosis and TreatmentRequires access

Research Progress on Monoclonal Antibody Therapy for Non-Hodgkin's Lymphoma

Hongmei Yuan

Abstract

Monoclonal antibody treatment has made great achievement in patients with malignant lymphomas.Comparing with traditional treatment,its advantages are targeted property and little side effect.It also could achieve mininal residal of tumor cell in vivo.The new anti-CD20 monoclonal antibody provides new development for treatment of non-Hodgkin's lymphoma and introduces a new strategy to the drug resistance.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Monoclonal antibody, Medicine, Lymphoma, Monoclonal antibody therapy, CD20, Rituximab, Cancer research, Immunology